Search results for "Morphine"

showing 10 items of 145 documents

Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study.

2007

The aim of this prospective cohort study was to confirm the safety of intravenous morphine (IV-M) used in doses proportional to the basal opioid regimen for the management of breakthrough pain and to record the nurse compliance on regularly recording data regarding breakthrough pain treated by IV-M. Over a one-year period, 99 patients received IV-M for breakthrough pain during 116 admissions. The IV-M dose was 1/5 of the oral daily dose, converted using an equianalgesic ratio of 1/3 (IV/oral). For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging problems when pain became severe (T0), and to reassess the patient 15minutes after IV-M injection (…

MalePalliative carePainCancer pain breakthrough-episodic pain intravenous morphineMedicineHumansProspective StudiesAdverse effectProspective cohort studyGeneral NursingAgedMorphinebusiness.industryPalliative CareMiddle AgedEquianalgesicClinical trialAnalgesics OpioidRegimenAnesthesiology and Pain MedicineOpioidAnesthesiaInjections IntravenousFemaleNeurology (clinical)businessCancer painmedicine.drugJournal of pain and symptom management
researchProduct

The use of high doses of oxycodone in an acute palliative care unit.

2010

A retrospective study of patients who were prescribed controlled-release oxycodone (CRO) in a period of 3 years (2006-2008) was performed. A total of 212 patients were prescribed at discharge CRO for background analgesia; 129, 43, and 40 patients were prescribed doses of oxycodone of less than 120 mg/day (group L), 120 to 240 mg/day (group M), and more than 240 mg/day (group L), respectively. No differences in gender, primary diagnosis, and pain mechanisms were found, but doses were significantly lower in older patients (P < .0005). At discharge, adverse effects were mild and only a minority of patients were switched to other opioids. This study demonstrated that CRO administered in lar…

MalePalliative carePainoxycodoneSettore MED/42 - Igiene Generale E ApplicataNeoplasmsmedicineHigh dosesHumansAdverse effectAgedRetrospective StudiesDose-Response Relationship Drugbusiness.industryPalliative CareAge FactorsRetrospective cohort studyGeneral MedicineMiddle Agedacute palliative care unitoxycodone; acute palliative care unit; trial clinicoAnalgesics OpioidDose–response relationshipDelayed-Action PreparationsAnesthesiaAcute DiseaseMorphineFemaletrial clinicobusinessCancer painOxycodonemedicine.drug
researchProduct

Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.

2014

Abstract Abstract Objective: The aim of this study was to assess the efficacy and tolerability of tapentadol (TP) for a period of 4 weeks in patients who were already treated by opioids. Methods: A convenience sample of 30 patients was selected for a prospective observational cohort study. Cancer patients who were receiving at least 60 mg of oral morphine equivalents were selected. Patients discontinued their previous opioid analgesics before starting TP, in doses calculated according the previous opioid consumption (1:3.3 ratio with oral morphine equivalents). The subsequent doses were changed according to the patients' needs for a period of 4 weeks. Oral morphine was offered as a breakthr…

MalePalliative careReceptors Opioid muAdverse effectSettore MED/42 - Igiene Generale E ApplicataCohort StudiesNeoplasmsReceptorsDrug Dosage CalculationsProspective StudiesAdverse effects; Cancer pain; Palliative care; TapentadolCancer painPain MeasurementAnalgesicsMorphineMedicine (all)General MedicineMiddle AgedTapentadolAnalgesics OpioidTapentadolTreatment OutcomeItalyTolerabilityAnesthesiaPalliative careFemaleDrugDrug Monitoringmedicine.drugCohort studyAdverse effects; Cancer pain; Palliative care; Tapentadol; Aged; Analgesics Opioid; Cohort Studies; Dose-Response Relationship Drug; Drug Dosage Calculations; Drug Monitoring; Female; Humans; Italy; Karnofsky Performance Status; Male; Middle Aged; Morphine; Neoplasms; Pain Management; Pain Measurement; Phenols; Prospective Studies; Receptors Opioid mu; Treatment Outcome; Pain; Medicine (all)PainOpioidDose-Response RelationshipPhenolsmedicineHumansPain ManagementKarnofsky Performance StatusAdverse effectAgedDose-Response Relationship DrugAdverse effectsbusiness.industryCancermedicine.diseaseOpioidmubusinessCancer pain
researchProduct

Development of tolerance to the antiaggressive effects of morphine

2001

Many reports have demonstrated that there is a development of tolerance to many effects produced by morphine. This study was conducted with the aim of determining whether the antiaggressive actions of morphine develop tolerance after chronic administration. Acute morphine administration produced antiaggressive effects which disappeared after chronic (7 days) treatment in isolated mice. An increase in non-social exploration was observed, representing morphine-induced hyperactivity, after acute treatment, which was not present after chronic administration. In conclusion, there is a development of tolerance to the antiaggressive and motor effects of morphine. Language: en

MalePharmacologyDose-Response Relationship DrugMorphineInjury controlAccident preventionbusiness.industryPoison controlDrug ToleranceMotor ActivitySuicide preventionOccupational safety and healthAggressionMicePsychiatry and Mental healthAnesthesiaInjury preventionExploratory BehaviorMorphinemedicineAnimalsSocial BehaviorbusinessAgonistic Behaviormedicine.drugBehavioral Pharmacology
researchProduct

Kinetic experiments on the synergistic effect of NADH on microsomal drug oxidation.

1974

Abstract1. The synergistic effect of NADH on the NADPH-dependent mixed function oxidation of p-nitroanisole and hexobarbital can be measured both photometrically and by following the substrate-induced oxygen consumption. The increase in reaction rate is about 50% and lasts as long as NADH is present in the microsomal suspension.2. The oxidation of added NADH is increased by hexobarbital, ethylmorphine and SKF 525-A. Lineweaver-Burk transformation of the NADH oxidation rates yields straight lines for xenobiotic substrates suggesting Michaelis constants similar to those obtained from metabolic experiments. NADH oxidation in the absence of NADPH is about half as rapid as in its presence.3. Som…

MalePyridinesHealth Toxicology and MutagenesisCyanidechemistry.chemical_elementHexobarbitalAnisolesToxicologyPhotochemistryBiochemistryOxygenMixed Function Oxygenaseschemistry.chemical_compoundOxygen ConsumptionPhenolsmedicineOrganic chemistryAnimalsPharmacologyCarbon MonoxideAniline CompoundsChemistryProadifenDrug SynergismGeneral MedicineMetyraponeEthylmorphineNADNitro CompoundsRatsHexobarbitalPharmaceutical PreparationsSpectrophotometryReagentPhenobarbitalMicrosomeMicrosomes LiverXenobioticChloromercuribenzoatesOxidation-Reductionmedicine.drugCarbon monoxideXenobiotica; the fate of foreign compounds in biological systems
researchProduct

Effects of CNQX and MPEP on sensitization to the rewarding effects of morphine

2011

The present study was conducted to evaluate the influence of the glutamatergic receptors α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and metabotropic glutamate 5 (mGlu5) receptors on sensitization to the rewarding effects of morphine. The effects of pre-treatment with saline or 20 mg/kg morphine plus the AMPA receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (5 or 10 mg/kg) or the metabotropic Glu5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) (5 or 10 mg/kg) on the place conditioning induced by a low dose of morphine (2 mg/kg) were assessed. The 2 mg/kg dose of morphine was ineffective in animals pre-treated with saline but induced a clear con…

MalePyridinesmedicine.drug_classReceptor Metabotropic Glutamate 5AMPA receptorPharmacologyReceptors Metabotropic GlutamateMicechemistry.chemical_compoundRewardmedicineAnimalsReceptors AMPASensitization6-Cyano-7-nitroquinoxaline-23-dionePharmacologyDose-Response Relationship DrugMorphineAntagonistReceptor antagonistConditioned place preferencemedicine.anatomical_structureMetabotropic receptorchemistryAnesthesiaCNQXMorphineConditioning OperantExcitatory Amino Acid Antagonistsmedicine.drugEuropean Journal of Pharmacology
researchProduct

The pathogenetic role of adulterants in 5 cases of drug addicts with a fatal outcome

2013

The purpose of the present study is to determine the role of lidocaine, caffeine and dextromethorphan, used as adulterant substances, in five cases of drug overdose which have come to our attention. Taking into account the pharmacological mechanism, blood concentration and route of administration (intravenous) we evaluated the hypothesis that these substances could act with a synergistic effect - or at least additive - with the illicit drugs on the central nervous system and cardiovascular system.

MalePyrrolidinesDrug ContaminationLidocainePharmacologyKidneyDextromethorphanDrug Userschemistry.chemical_compoundBileAnesthetics LocalForensic PathologyLungAdulterantMorphineDextromethorphanGastrointestinal ContentsLiverFemaleDrug ContaminationCaffeineSelective Serotonin Reuptake Inhibitorsmedicine.drugAdultNarcoticsSubstance-Related DisordersCitalopramDrug overdosePathology and Forensic MedicineForensic ToxicologyRoute of administrationAdulterantsCaffeinemedicineHumansBrain ChemistryMorphine DerivativesCodeineIllicit Drugsbusiness.industryForensic toxicologyAdulterants Lidocaine Caffeine DextromethorphanLidocainemedicine.diseaseVitreous BodyAntitussive AgentschemistryCentral Nervous System StimulantsDrug OverdosebusinessLawMethadoneForensic Science International
researchProduct

Selective action of two aporphines at alpha 1-adrenoceptors and potential-operated Ca2+ channels.

1993

Abstract Contractions evoked by noradrenaline (1 μM) or a depolarizing solution of 60 mM KCI were concentration dependently depressed by the aporphine alkaloids (S)-boldine and (R)-apomorphine in rataorta. Both drugs had a greater inhibitory potency on the contraction elicited by noradrenaline. Dose-response curves for noradrenaline were shifted to the right in presence of (S)-boldine. (R)-Apomorphine acted by a complex mechanism at α 1 -adrenoceptors and its inhibitory effects was irreversible. The conformational features of these alkaloids may explain their different behaviour at α 1 -adrenoceptors. In Ca 2+ -free solution, the alkaloids inhibited the contraction evoked by noradrenaline b…

MaleReceptor complexAporphinesApomorphineStereochemistryPhosphodiesterase InhibitorsMolecular ConformationIn Vitro TechniquesMuscle Smooth VascularPotassium Chloridechemistry.chemical_compoundNorepinephrineRadioligand AssaymedicinePrazosinBoldineAnimalsAporphineRats WistarEvoked PotentialsPharmacologyMembranesAlkaloidDihydropyridinePhosphodiesteraseReceptors Adrenergic alphaRatsAntitussive AgentsMechanism of actionchemistryCattleCalcium Channelsmedicine.symptommedicine.drugMuscle ContractionEuropean journal of pharmacology
researchProduct

Opioid plasma concentration during switching from morphine to methadone: Preliminary data

2003

Opioid switching is often used to improve the opioid response in cancer patients experiencing poor analgesia or adverse effects. However, no data are available on plasmatic changes of opioids and their metabolites during these phases, and whether there exists a relationship with the clinical events. In a prospective study of 10 consecutive cancer patients on oral morphine but with uncontrolled pain (greater >4 on a numerical scale of 0 to 10) and/or moderate to severe opioid adverse effects (on a level of 2 and 3 of a verbal scale) and not responsive to adjuvant medications, switching to oral methadone was performed using a fixed ratio of 5:1, leaving extra-doses of 1/5 of the daily dose of…

MaleTime FactorsAdministration OralAdverse effectDrug Administration ScheduleNeoplasmsBlood plasmamedicineHumansProspective StudiesCancer painProspective studyProspective cohort studyAdverse effectAgedDose-Response Relationship DrugMorphinebusiness.industryMiddle AgedPain IntractableAnalgesics OpioidTreatment OutcomeOpioidOncologyAnesthesiaToxicitySwitchingMorphineFemaleAnalgesiabusinessCancer painMethadonemedicine.drugMethadone
researchProduct

The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients

2012

Abstract OBJECTIVES: The aim of this study was to evaluate the opioid response in patients receiving morphine and pregabalin, independently from the presumed pain mechanisms, in comparison with patients receiving morphine treatment only. METHODS: A multicenter prospective randomized controlled study was carried out in a sample of 70 advanced cancer patients with pain requiring strong opioids. Thirty-five patients (group MO) were randomized to receive sustained-release morphine using initial doses of 60 mg/day. Thirty-five patients (group MO-PR) were randomized to start the same morphine doses and pregabalin in increasing doses, starting with 25 mg/day up to 150 mg/day in one week. The follo…

Malecancer painAnalgesicPregabalinPregabalinPainSettore MED/42 - Igiene Generale E Applicatalaw.inventionDose-Response Relationshipadvanced cancer patientDrug TherapyQuality of lifeRandomized controlled triallawassessment toolsNeoplasmsmedicineHumansDrug Interactionslow doses pregabalinBrief Pain Inventorygamma-Aminobutyric AcidPain Measurementneuropathic painAnalgesicsDose-Response Relationship DrugMorphinebusiness.industryassessment tools; cancer pain; neuropathic pain; opioid response; Analgesics; Dose-Response Relationship Drug; Drug Interactions; Drug Therapy Combination; Female; Humans; Italy; Male; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Pregabalin; Treatment Outcome; gamma-Aminobutyric Acid; Anesthesiology and Pain Medicine; Neurology (clinical)Palliative CareAdvanced cancerTreatment OutcomeAnesthesiology and Pain MedicineItalyOpioidlow doses pregabalin; advanced cancer patients; epidemiologic studyopioid responseAnesthesiaCombinationepidemiologic studyMorphineDrug Therapy CombinationFemaleNeurology (clinical)Drugbusinessmedicine.drug
researchProduct